

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MARTINEZ *et al.*

Appl. No.: 10/669,597

Filed: September 25, 2003

For: **Polymer Conjugates with
Decreased Antigenicity, Methods
of Preparation and Uses Thereof**

Confirmation No.: 1312

Art Unit: 1654

Examiner: GUPTA, Anish

Atty. Docket: 2057.0040002/ELE/GER

Fourteenth Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on the accompanying IDS Form PTO/SB/08A are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98.

Copies of documents **FP16-FP23** are submitted.

Document FP17 (JP 2002-527491 A) is a foreign language document. Based on information and belief, document FP17 is a translation of WO 00/23114 A2, which is of record in the present application as document FP12. It is submitted that the English language document FP12 satisfies the requirement for a concise explanation of relevance for document FP17. M.P.E.P. 609.04(a)III.

Document FP18 (JP 50-42087) is a foreign language document. An English language patent (U.S. Patent No. 4,179,337) in the same patent family as document FP18 is of record in the present application as document AE1. Based on U.S. Patent No. 4,179,337, document FP18 appears to relate to certain polypeptides that are coupled to

polyethylene glycol or polypropylene glycol having a molecular weight of 500 to 20,000 daltons.

Document FP19 (JP 53-24033) is a foreign language document. An English language patent (U.S. Patent No. 4,261,973) in the same patent family as document FP19 is of record in the present application as document US11. Based on U.S. patent No. 4,261,973, document FP19 appears to relate to allergen-containing substances that are covalent conjugates of the allergen molecules with water-soluble polymers.

Document FP20 (JP 08-283282 A) is a foreign language document. An English language document (WO 87/06838) is listed as document FP22. Based on WO 87/06838, document FP20 appears to relate to certain immunogenic conjugates.

Document FP21 (JP6-507410 (T)) is a foreign language document. Based on information and belief, document FP21 is a translation of WO 92/19273 A1, which is listed as document FP23. It is submitted that the English language document FP23 satisfies the requirement for a concise explanation of relevance for document FP21. M.P.E.P. 609.04(a)III.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Form based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Form, and indicate in the official file wrapper of this patent application that the documents have been considered.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. The required fee is provided through online credit card payment authorization in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

/Grant E. Reed/

Grant E. Reed
Attorney for Applicants
Registration No. 41,264

Date: March 4, 2011

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

1315808